Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
NCT ID: NCT06902493
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
664 participants
OBSERVATIONAL
2024-04-01
2025-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
NCT06124924
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients
NCT07302464
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615
EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY
NCT06288529
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06528405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SA-AKI Group
Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition and KDIGO criteria, respectively
No intervention
No intervention
No AKI group
Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Renal transplant or tumor
* Solitary kidney
* Established CKD
* Obstructive uropathy
* Renal artery stenosis
* Pregnancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Jazan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmad Abdullah Salawi
Associate Professor of Pharmaceutics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed Alshrahili, MSc
Role: PRINCIPAL_INVESTIGATOR
Armed Forces Hospitals, Southern Region, Saudi Arabia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Fahd Central Hospital
Al ‘Usaylah, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SGLT2I-AKI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.